

Cumulative Index 1991

Volume 11

<i>March</i>	LABORATORY AND HOSPITAL INFORMATION SYSTEMS, pages 1-270
<i>June</i>	VALUE AND LIMITATIONS OF CYTOLOGIC EXAMINATIONS, pages 271-508
<i>September</i>	LABORATORY TESTING IN ORGAN TRANSPLANTATION, pages 509-810
<i>December</i>	DIAGNOSIS OF IMPORTANT PARASITIC DISEASES, pages 811-1089

Note: Page numbers for complete issues and articles appear in **boldface** type.

- ABEL expert system, 145
 ABO blood group incompatibility, in graft rejection, 538, 544, 592
 Abscess, amebic, 849-850
 cytology in, breast, 358-359
 head and neck, 334
 liver, 343
 lung, 311
Acanthamoeba, in dermatitis, 871
 in granulomatous encephalitis, 861-866
 in keratitis, 870-871
 in pneumonitis, 871
 Accounting, information systems for, 87-88, 166
 Accreditation. *See* *Laboratory regulation*.
 Acid-base electrolyte program (ABEL), 145
 Acinar cell carcinoma, pancreatic, cytology in, 349
 Acinic cell carcinoma, of salivary glands, cytology of, 329, 331
 Acquired immunodeficiency syndrome, pulmonary cytology in, 295-296, 310-313
 toxoplasmosis in, 934-935
 Acute-phase proteins, in liver graft rejection, 662
 Acute tubular necrosis, urinary sediment cytology in, 745
 Adenocarcinoma, cytology in, bile duct, 338, 340
 cervical, 282-286
 colon, 424-429, 435
 effusion, 450-451
 endometrial, 286-289
 esophageal, 408-409
 extrauterine, 289-290
 gastric, 418-419
 in liver metastasis, 341
 lung, 301-306
 pancreatic, 345, 347
 prostate, 388-389, 391
 vs. adenoma, 435
 Adenocarcinoma in situ, cervical, cytology in, 283-284
 Adenoid cystic carcinoma, of salivary glands, cytology in, 329
 Adenoma, cytology in, colon, 434-436
 gastric, 421-422
 hepatocellular, 340
 pancreatic, 351
 salivary glands, 326-327
 thyroid, 318-319
 Affinity column-mediated immunoassay, in cyclosporine A monitoring, 678
 African trypanosomiasis, 899-905
 clinical features of, 902
 epidemiology of, 901-902

- African trypanosomiasis (*Continued*)
 laboratory diagnosis of, 903-905
 late stage, 904-905
 organisms causing, 899, 901
 trypanotolerance in, 902-903
- Agglutination test. See also
Hemagglutination test.
 direct, in leishmaniasis, 920
 in toxoplasmosis, 928-929
 immunosorbent, in toxoplasmosis, 930
 in trypanosomiasis, 903
 latex, in toxoplasmosis, 929
- Alkaline phosphatase levels, in liver graft
 monitoring, 658-659
- Alloantibodies. See also *Antibody(ies)*, in
transplantation, donor-specific.
 removal of, before transplantation, 544
 to HLA, anti-idiotypic-like, 633-652
 laboratory detection of, 640-642
 networks in, 637-640
 relevance of, 643-645
 T-cell regulation and, 646-647
 terminology of, 635-637
 cell panel for, 556-557
 characteristics of, 552-555
 crossmatching strategy and, 564-567
 screening interpretation of, 563-564
 screening procedures for, 555-562
 screening strategy for, 562-563
- Alloantigens, presensitization to, 543-544
- T-cell receptor recognition of, 540-541
- T-cell response to, in graft rejection, 539-540
- Allograft rejection. See *Graft rejection*.
- Alloimmunization. See also *Alloantibodies*.
 predictive testing in, 768-769
 to HLA, 551-570
 epitopes in, 552-555
 in crossmatch procedures, 607
 induction of, 552
 loss of, monitoring of, 643-644
 private epitopes in, 552-555
 public epitopes in, 552-555
- Amastigotes, visualization of, in
 leishmaniasis diagnosis, 912-917
- Amebas, free-living, 861-872
 in acanthamoebic infections, 870-871
 in granulomatous amebic encephalitis,
 866-870
 in meningoencephalitis, 861-866
- Amebiasis, 829-859
 diagnosis of, antigen detection in, 853-854
 circulating immune complexes in, 853
 immunoglobulin M detection in, 853
 immunologic methods in, 850-852
 molecular technology in, 854
 specimen collection for, 831-832
 specimen concentration for, 840-842
 specimen preservation for, 832-836
 staining in, 838-839, 842-844
 temporary wet mounts in, 837-839
 epidemiology of, 830
 extraintestinal, 849-850
 of liver, 849-850
 parasite of (*Entamoeba histolytica*), 829-830
 cysts of, 829-830, 846-847
 hematophagous form of, 830
 in vitro cultivation of, 847-849
 morphology of, 844-847
 trophozoites of, 829-830, 844-846
- American trypanosomiasis, 905-908
- Amphotericin B, in amebic
 meningoencephalitis, 866
- Amylase, in pancreas graft rejection, 663
- ANA-BEL expert system, 145
- Anal intraepithelial neoplasia, cytology in,
 430-431
- Analysis of Acid-Base Status by Evaluating
 Liss system, 145
- Anaplastic carcinoma, thyroid, cytology in,
 322
- Angiomyolipoma, renal, cytology in, 384
- Angiosarcoma, liver, cytology in, 340
- Animal pathogenicity tests, in free-living
 amebic infections, 865
- Anion exchange centrifugation test, in
 African trypanosomiasis, 904
- Anti-human-globulin-augmented cytotoxicity
 test, in crossmatching, 610
- Anti-idiotypic antibodies, definition of, 636-637
 development of, 638-640
 in alloimmunization. See under *Alloantibodies*.
 in pretransplant enhancement, 644-645
 laboratory detection of, 640-642
 nonsite-associated, 636
 posttransplant, 589, 591-592
 site-associated, 636
 testing for, 578-579
 to OKT3, development of, 700-703
- Anti-isotype antibodies, to OKT3,
 development of, 702-703
- Anti-mouse immunoglobulin G antibodies,
 interference with OKT3 assays, 768
- Anti-OKT3 antibodies, development of,
 700-703
- Antibody(ies), in transplantation, donor-
 specific, 571-602
 anti-Cw-induced rejection, 581
 anti-idiotypic, 578-579, 589
 autolymphocytotoxic, 588
 definition of, 572
 endothelial antigen system in, 576-578, 587-588
 epithelial antigen system in, 576-578
 in hyperacute rejection, 581

- in predicting positive crossmatches, 579-580
- induction of, 571-572
- low-affinity, 588, 592
- management of highly sensitized patients in, 582-583
- monocyte expression of, 576-578
- of heart, 585-589
- of kidney, 573-585
- of liver, 590-593
- of pancreas, 593-595
- poor match consequences and, 580-581
- positive donor lymphocyte cross-match in, 573-576, 585-587, 590-591, 593
- posttransplant, 581-582, 588-589, 591-592, 644
- removal of, 582
- repeat antigen mismatch and, 580
- suppression of, 582 pretransplant transfusions in, 633-634, 644-645
- to *Giardia*, 821-823
- to non-HLA antigens. See under *Antigen(s), non-HLA*.
- Antibody-dependent cell-mediated cytotoxicity test, in kidney graft monitoring, 737
- Antigen detection tests, in cysticercosis, 1018
 - in filariasis, 994-996, 998, 1002, 1005
 - in pneumocystosis, 970
- Antigen(s), HLA. See *HLA*.
- non-HLA, antibodies to, 621-632
 - clinical significance of, 629
 - gamma interferon effects on, 627
 - in B cells, 628
 - in endothelial cells, 622-624, 626
 - in graft rejection, 622
 - in keratinocytes, 626-627
 - in monocytes, 624, 627-628
 - skin crossmatching and, 625
 - characteristics of, 628-629
 - prior mismatch of, graft survival and, 580
- to *Entamoeba*, detection of, 853-854
- Antigen detection tests, in cysticercosis, 1017
 - in filariasis, 999-1000, 1005
 - in free-living amebic infections, 864
 - in pneumocystosis, 970-971
 - in toxoplasmosis, 931
- Antigen-presenting cells, allogeneic, in graft rejection, 539-540
- Antigen-trapping ELISA technique, in African trypanosomiasis, 903
- Antiglobulin-augmented complement-dependent cytotoxicity assay, in anti-idiotypic antibody detection, 641-642
- in HLA alloantibody screening, 555-556, 559-562
- Apocrine carcinoma, breast, cytology in, 367
- Asbestos bodies, in pulmonary cytology, 313
- Aspergillosis, pulmonary cytology in, 312
- Aspiration, needle. See *Needle aspiration*.
- Atherosclerosis, in heart graft, 589
- Australia, laboratory regulation in, 777-791
 - accreditation authorities for, 781-784
 - Commonwealth Department of Community Services and Health in, 781-782
 - education authorities in, 788-790
 - history of, 778-779
 - inspecting authorities in, 786-788
 - National Pathology Accreditation Advisory Council in, 779-781
 - payment authorities in, 784-786
 - quality assurance program authorities in, 788
 - staff qualifications and, 783-784
 - standards authorities for, 779-781
 - Victorian Pathology Services Accreditation Board in, 782-783
- Australian Association of Clinical Biochemists, 789
- Australian Institute of Medical Laboratory Scientists, 789
- Australian Society for Microbiology, 790
- Autoantibodies, adsorption of, in crossmatch procedures, 608
- Autoimmunization, to HLA, in crossmatch procedures, 607
- Autolymphocytotoxic antibodies, in crossmatch procedures, 607-608
- in heart transplantation, 588
- Automation, information systems in. See *Information systems*.
- B cell(s), endothelial antigens expressed on, 628
 - enrichment with, for crossmatch procedures, 606
- Bacteremia, in liver transplantation, vs. rejection, 656
- Bacterial infections, in transplant patients, 720
- Bar codes, in information systems, 227-238
 - applications of, 234-236
 - barriers to, 236-237
 - blood bank labelling with, 235
 - clinical laboratory, 231-233
 - industrial, 231
 - patient identification with, 234-235
 - readers for, 230-231
 - standard structure for, 236-237
 - symbolology in, 228-229
- Barrett's dysplasia, cytology in, 412-413

- Barrett's esophagus, cytology in, 407-408
 BASIC language, 30-31, 56
 Benign lymphoepithelial lesion, of salivary glands, cytology in, 331
 Beta-2-microglobulin, in liver graft rejection, 662
 Bethesda system, for gynecologic cytology, 273-279
 Bile cytology, in liver graft monitoring, 661
 Bile duct adenocarcinoma, cytology in, 338, 340
 Bilirubin levels, in liver graft monitoring, 658-659
 Billing, for hospital-based pathology services, 1052-1054, 1060-1061
 for hybrid laboratories, 161-166
 Biochemical diagnosis, of malaria, 951
 Biopsy, in graft monitoring, before OKT3 therapy, 707
 endomyocardial, 663-664, 742
 fine needle aspiration, 655-659, 663, 743-744
 liver, 655-659
 pancreas, 663
 in pneumocystosis diagnosis, 961, 963
 needle. See *Needle aspiration*.
 of leishmaniasis lesion, 916-917
 of skin, microfilariae detection in, 984-985
 BK papovavirus infection, in transplant patients, 721
 Bladder, tumors of, cytology in. See *Urinary cytology*.
 washing of, urine specimen from, 375
 Blood, in pulmonary cytology, 312-313
 lymphocyte isolation from, for transplantation crossmatching, 605
 Blood bank, bar code labelling in, 235
 Blood smear, stained, in filariasis diagnosis, 979-981
 Boech and Drobhavl's medium, for amebae cultivation, 848
 Branchial cleft cyst, cytology in, 334
 Breast lesions, cytology of, 357-368
 benign, 359-362
 malignant, 362-367
 metastasis to liver, 341
 nonneoplastic, 358-359
 technique for, 357
 vs. normal tissue, 358
 Bronchial atypia, vs. adenocarcinoma, 303-306
 Bronchial brushings/washings, for cytology, 295
 Bronchiectasis, cytology in, 311
 Bronchiolar carcinoma, cytology in, 301-306
 Bronchitis, cytology in, 311
 Bronchoalveolar lavage, cytology of, 295-296
 in lung graft monitoring, 664-665
 in pneumocystosis diagnosis, 961
Brugia malayi infection. See *Filariasis*.
 Brush cytology, bronchial, 295
 in colon adenocarcinoma, 425-429
 in gynecology, 273
 in ulcerative colitis, 432-433
 Burkitt's lymphoma, cytology in, 481-482
 C-dependent cytotoxicity assay, 555-556, 609-610, 737
 C language, 59, 62, 69
 Candidiasis, esophageal, cytology in, 404
 in transplant patients, 724
 Carcinoid tumors, of stomach, cytology in, 422-423
 Carcinoma. See also *Adenocarcinoma*.
 acinar cell, cytology in, 349
 acinic cell, cytology in, 329, 331
 adenoid cystic, cytology in, 329
 anaplastic, of thyroid, cytology in, 322
 apocrine, cytology in, 367
 breast, cytology in, 362-367
 bronchiolar, cytology in, 301-306
 colon, metastasis to liver, 341
 cyst-containing, cytology in, 334
 effusions in, 448-454
 follicular, of thyroid, cytology in, 319
 hepatocellular, cytology in, 337-338
 large-cell. See *Large-cell carcinoma*.
 lung. See *Pulmonary cytology*.
 medullary. See *Medullary carcinoma*.
 metastatic, cytology in, to liver, 340-342
 to neck lymph nodes, 334
 mucinous, cytology in, 367
 mucocypidermoid, cytology in, 327, 329
 oat-cell. See *Small-cell carcinoma*.
 pancreatic, cytology in, 349-351
 papillary. See *Papillary carcinoma*.
 renal cell, cytology in, 382, 384, 386
 signet-ring, cytology in, 451
 squamous cell. See *Squamous cell carcinoma*.
 thyroid, cytology in, 319-322
 transitional cell, urinary cytology in, 377, 381
 undifferentiated, cytology in, effusion, 454
 esophageal, 414
 urinary tract. See *Urinary cytology*.
 Carcinoma in situ, cytology in, bladder, 373, 376
 cervical, 277, 279
 Card agglutination trypanosomiasis test, 903
 Carotid body paraganglioma, cytology in, 333
 Catheterization, urine specimen from, 375
 Cavernous hemangioma, of liver, cytology in, 340
 CD cells. See under *Lymphocyte(s)*.

- Cell-mediated lympholysis, in HLA typing, 514, 544
- Cellophane tape test, in cysticercosis, 1019
- Centrifugation, in African trypanosomiasis diagnosis, 904
- in filariasis diagnosis, 981
- in malaria diagnosis, 950-951
- Cerebrospinal fluid examination, in African trypanosomiasis, 904-905
- in cysticercosis, 1016-1018
- in granulomatous amebic encephalitis, 867-868
- Cervical disorders, cytology in, adenocarcinoma, 282-286
- carcinoma in situ, 277, 279
- human papillomavirus lesions, 281-282
- small-cell carcinoma, 279-280
- squamous cell carcinoma, 280-282
- Cervical epithelial lesions, microinvasive squamous cell carcinoma, 280
- preneoplastic/early neoplastic, 273-280
- classification of, 275-276
- cytologic features of, 277, 279
- cytoplasmic differentiation of, 279-280
- histopathology of, 276-277
- keratinization of, 279
- Cervical intraepithelial neoplasia classification system, 276
- Cervicovaginal cytology. See *Gynecologic cytology*.
- Chagas disease, 905-908
- Chemiluminescence immunoassay, in cyclosporine A monitoring, 678
- Chemotherapy, cell changes in, bladder, 380
- esophagus, 411-412
- prostate, 392
- Chlamydial infection, cytology in, 282
- Chloroma, cytology in, 488-489
- Cholangiocarcinoma, cytology in, 338, 340
- Cholestasis, in liver graft, vs. rejection, 658
- Chromatography, high performance liquid, in cyclosporine A monitoring, 675-676
- Chromium-release assays, in transplantation crossmatching, 615
- Circulating immune complexes, in transplantation, 579
- Cirrhosis, cytology in, 343
- CLAS expert system, 148
- COBOL, 7, 30-31, 56, 68-69
- Codes, bar. See *Bar codes*.
- for pathology services billing, 1057-1060
- Colitis, cytology in, cytomegalovirus, 429-430
- ulcerative, 431-434
- Colloid goiter, cytology in, 318
- Colon disorders, cytology in, 424-436
- adenocarcinoma, 424-429
- metastatic to lung, 301-303
- adenoma, 434-436
- anal intraepithelial neoplasia, 430-431
- carcinoma, metastatic to liver, 341
- cytomegalovirus colitis, 429-430
- Kaposi's sarcoma, 436
- ulcerative colitis, 431-434
- Commercialism, in laboratory regulation, 800-801
- Commonwealth Department of Community Services and Health Accreditation Branch (Australia), 781-782
- Communication, in information systems. See under *Information systems*.
- Competitors, of hospital laboratories. See under *Hospital laboratories*.
- Complement, in kidney graft rejection, 737
- Complement-dependent cytotoxicity assay, in anti-idiotypic antibody detection, 641-642
- in kidney graft monitoring, 737
- in transplantation crossmatching, 609-610
- Complement factor analysis, expert systems for, 145-146
- Complement fixation test, in American trypanosomiasis, 906
- in toxoplasmosis, 928
- Computed tomography, in cysticercosis, 1015
- Computerized Laboratory Alerting System (CLAS), 148
- Computers, acquisition of, 1-20
- general principles of, 1-7
- vendor selection in, 21-39
- aversion to, 49
- compilers in, 6-7, 56
- components of, 54-55
- dialogue with, 17
- display features of, 14-15, 131-132
- error messages of, 16
- flexibility of, 13-14
- friendliness of, 13-14
- graphical user interface in, 126-128
- hardware risks in, 30
- in workstations. See *Information systems, workstations for*.
- input devices for, 126
- interpreters in, 56
- life cycle of, 6-7
- maintenance of, 37-38, 48
- output devices for, 126
- performance limits of, 70-71
- personal, languages for, 59-60
- learning from, 2-3
- programming languages for. See *Languages, programming*.
- reliability of, 15
- requirements of, 13-17
- software for. See *Software*.
- strengths of, 3-5
- user interface of, 126-128
- weaknesses of, 3-5

- Computers (*Continued*)
 windowing systems in, 127-128
 Concavalin A test, in kidney graft monitoring, 738
 Concentration procedures, for filariasis diagnosis, 981-984
 for stool specimen, 819, 840-844, 884
 Condylomata, human papillomavirus, cytology in, 281-282
 Consultation, for information systems, 8-9
 Contract, for information system acquisition, 34-39
 for pathology services, 1052
 Coproantigen detection, in cysticercosis, 1020
 Costs, of information systems. See under *Information systems*.
 Cough induction, for sputum cytology, 294
 Counterimmunoelectrophoresis, in American trypanosomiasis, 906-907
 in giardiasis, 822
 Crossmatch procedures, in transplantation, 603-620, 766-767. See also *Mismatch*.
 chromium-release assays in, 615
 clinical relevance of, 615-617
 complement-dependent cytotoxicity assays in, 609-610
 donor-specific antibodies and, 573-576, 579-580
 flow cytometry in, 610-615
 historical aspects of, 604
 HLA typing, 734-735
 in HLA alloimmunization, 564-567
 negative results in, early allograft rejection in, 622
 positive results in, vs. hyperacute rejection, 586-587
 practical considerations for, 541-542
 recipient sera for, 607-608
 skin samples for, 625-629
 target cell isolation in, 604-606
 Crossreactivity, of HLA class I, 516-517
 Cryptococcosis, in transplant patients, 725
 Cryptosporidiosis, 873-897
 clinical features of, 882-883
 diagnosis of, histologic, 883
 laboratory, 883-887
 epidemiology of, 878-881
 etiologic agent of, 876-878
 in HIV-infected persons, 881
 parasite of, life cycle of, 876-878
 sources of, 880
 taxonomic relationships of, 876
 prevalence of, 880-881
 transmission of, 878-880
 treatment of, 887-889
 Culture, of *Entamoeba histolytica*, 848-849
 of *Leishmania*, 917-919
 Cyclophosphamide, in OKT3 therapy, 709
 Cyclosporine A monitoring, in transplantation, 671-691
 affinity column-mediated immunoassay in, 678
 area under curve, 686-687
 chemiluminescence immunoassay in, 678
 dilemmas in, 672-674
 enzyme-multiplied immunoassay in, 678
 fluorescence polarization immunoassay in, 677-678
 high performance liquid chromatography in, 675-676
 lymphokine assay in, 752, 754, 756-757
 metabolite interference in, 673-674
 methods for, 674-678
 correlations among, 684
 pharmacokinetics in, 686-687
 radioimmunoassay in, 674-677
 sample matrix for, 672-673
 trough, 686
 urinary sediment cytology in, 745-749
 Cyst(s), *Entamoeba*, 829-830, 847-848
 Giardia, 813, 816
 Cystadenoma, serous, of pancreas, cytology in, 351
 Cystic lesions, cytology in, breast, 359
 liver echinococcus cyst, 343
 neck, 334
 pancreas, 351
 renal, 384-385
 Cysticercosis, 1011-1028
 clinical diagnosis of, 1014-1015
 epidemiology of, 1012, 1014
 laboratory diagnosis of, fecal examination in, 1018-1020
 future prospects for, 1023
 immunologic, 1015-1018
 lumbar puncture in, 1018
 parasite of, 1011-1012, 1014
 pathogenesis of, 1012
 public health aspects of, 1022-1023
 radiologic diagnosis of, 1015
 tissue diagnosis of, 1020-1021
 transmission of, 1011-1012
 treatment of, 1021-1022
 Cystosarcoma phyllodes, of breast, cytology in, 360
 Cystoscopy, urine specimen from, 375
 Cytobrush, in gynecologic cytology, 273
 Cytoimmunologic monitoring, of heart graft, 664, 742-743
 Cytology, breast, 357-368
 bronchial, 295
 bronchoalveolar lavage, 295-296
 cervicovaginal, 271-292
 colon, 424-436
 effusion, 443-467
 esophageal, 404-415
 gastrointestinal, 403-441

- genitourinary, 369-401
 gynecologic, 271-292
 head and neck tumors, 317-336
 in graft monitoring, bile, 661
 exfoliative, 743-744
 pancreatic juice, 663
 urinary sediment, 744-749
 in leukemia, 469-499
 in lymphoma, 469-499
 kidney, 381-387
 liver, 336-344
 needle aspiration in. See *Needle aspiration*.
 pancreas, 344-352
 prostate, 387-393
 pulmonary, 293-315
 salivary glands, 325-332, 334
 sputum, 294-295
 stomach, 415-424
 testis, 393-394
 thyroid, 317-324, 334
 urinary, 369-381
 Cytomegalovirus infection, cytology in,
 colitis, 429-430
 pulmonary, 311
 in transplant patients, 716-718, 720-722,
 725, 728-729
 liver, vs. rejection, 657, 660-661
 lymphokine assay in, 750-752
- D'Antoni's iodine, in amebiasis diagnosis,
 838-839
 Data base, access to, 129-130
 centralized, 223-224
 Data management. See *Information systems*.
 Decision-oriented test request forms, 255-
 265
 Degenerative changes, in liver graft, 658
 Delta checking, in information systems,
 100-101
 Density gradient separation, in lymphocyte
 isolation, for crossmatch procedures,
 605
 Dermatitis, *Acanthamoeba* in, 870
 Diarrhea, in cryptosporidiosis, 882-883
Dientamoeba fragilis, 829, 843, 845, 847
 Direct agglutination test, in leishmaniasis,
 920
 in toxoplasmosis, 928-929
 DNA probes, in amebiasis, 854
 Donor-specific antibodies. See under
 Antibody(ies).
 Dot blot analysis, in HLA analysis, 515
 Dyskeratocytes, in cervical lesions, 281
 Dyslipoproteinemia, expert systems for, 145
 Dysplasia/carcinoma in situ classification, of
 cervical lesions, 276
- E-M antigens, in transplantation testing,
 577-578
 early studies of, 622-624
 E-mail, in result reporting, 243-244
 Echinococcus cyst, liver, cytology in, 343
 Education, in laboratory accreditation, 788-
 790
 Effusion cytology, 443-467
 diagnostic accuracy of, 444-445
 in adenocarcinoma, 450-451
 in extramedullary hematopoiesis, 462
 in infections, 462
 in leukemia, 454-456
 in lymphoma, 454-456, 460
 in malignancy, 448-457
 in melanoma, 457
 in mesothelial hyperplasia, 446-448
 in mesothelioma, 448, 457-460
 in poorly differentiated malignancy, 460-
 461
 in primary site prediction, 461-462
 in rheumatoid disease, 462
 in sarcoma, 456-457, 460
 in small-cell carcinoma, 451, 454
 in squamous cell carcinoma, 451
 in trauma, 463
 in undifferentiated large-cell carcinoma,
 454
 preparatory methods for, 443-444
 Eggs, detection of, in cysticercosis, 1018-
 1020
 Electron microscopy, in free-living amebic
 infections, 864-865, 869
 Electronic systems. See *Computers*;
 Information systems.
 Electrophoresis, gel. See *Gel*
 electrophoresis.
 ELISA. See *Enzyme-linked immunosorbent*
 assay.
 Encephalitis, amebic, from *Naegleria*
 fowleri, 861-866
 granulomatous, 866-870
 toxoplasmic, 934-935
 Endocervical adenocarcinoma, cytology in,
 282-286
 Endocervical dysplasia, cytology in, 283-284
 Endocervical smears, sampling for, 273
Endolimax nana, 829, 845
 Endometrium, adenocarcinoma of, cytology
 in, 286-289
 hyperplasia of, cytology in, 286-287
 out-of-phase cells in, 287
 smear sampling from, 273
 Endomyocardial biopsy, in heart graft
 monitoring, 663-664, 742
 Endoscopic retrograde pancreatography,
 cytologic specimens from, 344-345
 Endothelial antigens, antibodies to, in heart
 transplantation, 587-588
 characteristics of, 628-629

- Endothelial antigens (*Continued*)
 in transplantation testing, 576-578
 early studies of, 622-624
 skin crossmatch procedures for, 625-629
- Entamoeba coli*, 829, 838, 843, 844, 847
- Entamoeba hartmanni*, 829, 837-838, 844-847
- Entamoeba histolytica*. See *Amebiasis*, *parasite of*.
- Entamoeba polecki*, 829, 845-847
- Enzyme immunoassay, in American trypanosomiasis, 907
- in toxoplasmosis, 929-930
- Enzyme-linked immunoelectrotransfer blot test, in cysticercosis, 1016-1017
- in schistosomiasis, 1034-1035
- Enzyme-linked immunosorbent assay (ELISA), Falcon assay screening test (FAST), in schistosomiasis, 1031-1034
- in amebiasis, 852-854
- in anti-OKT3 antibody detection, 707-708
- in cysticercosis, 1016
- in filariasis, 995, 998
- in giardiasis, 821-823
- in leishmaniasis, 919-920
- in toxoplasmosis, 929
- Enzyme-multiplied immunoassay, in cyclosporine A monitoring, 678
- Eosinophilia, in liver graft rejection, 662
- Epithelial antigens, in transplantation testing, 576-578
- Epithelial repair, cytology in, in esophageal inflammation, 406-407
- in stomach inflammation, 415-417
- Epitopes, private, in HLA alloimmunization, 552-555
- public, in HLA alloimmunization, 552-555
- Epstein-Barr virus infection, in transplant patients, 717-718, 721-722, 727
- Erythropoietin, in donor-specific antibody development prevention, 582
- Esophageal disorders, cytology in, 404-415
- adenocarcinoma, 408-409
- Barrett's dysplasia, 412-413
- Barrett's esophagus, 407-408
- candidiasis, 404
- chemotherapy injury, 411-412
- epithelial repair, 406-407
- gastroesophageal reflux, 406-407, 414-415
- herpes esophagitis, 404-406
- pemphigus vulgaris, 414
- radiation esophagitis, 411-412
- squamous cell carcinoma, 409-410
- squamous cell dysplasia, 413-414
- undifferentiated carcinoma, 414
- ESPRE expert system, 142
- Exfoliative cytology, in transplant recipient monitoring, 743-744
- EXPERT expert system, 138, 142
- Expert systems, in laboratory information system, 135-151
- Eye, toxoplasmosis manifestations in, 925, 934
- FAB classification, of leukemia, 473-475
- Falcon assay screening test (FAST) enzyme-linked immunosorbent assay, in schistosomiasis, 1031-1034
- Fat necrosis, of breast, cytology in, 358
- Fecal specimen. See *Stool examination*.
- Fibroadenoma, of breast, cytology in, 360
- Fibrocystic mastopathy, cytology in, 359
- Filariasis, diagnosis of, 977-1010
- approaches to, 1005-1007
- immunologic, 993-1001
- antibody detection in, 994-995, 998, 1002, 1005
- antigen detection in, 999-1000, 1005
- molecular probes in, 1000
- lymphatic type, 994-995, 998-1000
- onchocerciasis, 1001-1002, 1005
- parasitologic, 978-991
- bloodborne microfilariae detection in, 979-981
- centrifugal concentration in, 981
- identification methods in, 985, 988, 991
- membrane filtration concentration in, 981-984
- skin microfilariae detection in, 984-985
- specimen collection for, 978-979
- stained blood smear in, 979
- parasites of, 977-978
- morphology of, 985, 988, 991
- Fine needle aspiration biopsy. See *Needle aspiration*.
- Flotation techniques, for fecal specimen concentration, 841-843
- Flow cytometry, in free OKT3 antibody detection, 706
- in graft monitoring, 739-740, 742-743
- in leukemia/lymphoma cytology, 475. See also specific type under *Lymphoma* and *Leukemia*.
- in malaria diagnosis, 949-950
- in T-cell detection, in OKT3 therapy, 704-706
- in transplantation crossmatching, 610-615
- in urinary cytology, 381
- Fluorescence activated cell sorter, in graft monitoring, 739-740
- Fluorescence polarization immunoassay, in cyclosporine A monitoring, 677-678

- Fluorescent microscopy, in malaria diagnosis, 947-948
- Focal nodular hyperplasia, of liver, cytology in, 340
- Follicular adenoma, thyroid, cytology in, 318-319
- Follicular carcinoma, thyroid, cytology in, 319
- Formalin-ether sedimentation technique, for fecal specimen concentration, 841
- Formalin solutions, for stool specimens, 835-836
- FORTAN, 6-7, 30-31, 56, 68-69
- Free antibody test, in OKT3 therapy, 706
- Fungal infections, cytology in, esophageal, 404
pulmonary, 311-312
in transplant patients, 724
- Gamma interferon, in endothelial antigen studies, 627
- Gastrinoma, cytology in, 350-351
- Gastritis, cytology in, 415-416, 420, 423-424
- Gastroesophageal reflux, cytology in, 406-407, 414-415
- Gastrointestinal cytology, 403-441
esophagus, 404-415
large intestine, 424-436
stomach, 415-424
- Gel-diffusion precipitins, in amebiasis, 851-852
- Gel electrophoresis, in endothelial antigen characterization, 628-629
in HLA class I analysis, 514
one-dimensional isoelectric focusing, 518
- Genitourinary cytology, 369-401
prostate, 387-393
renal, 381-387
testis, 393-394
urinary, 369-381
- Germ cell tumors, testicular, cytology in, 393-394
- Giardiasis, 811-827
chronic, 818
clinical presentation of, 818
diagnosis of, 818-821
experimental approaches in, 823
immunologic methods in, 821-823
epidemiology of, 816-818
parasite of, antigens to, 822-823
biology of, 811-813
life cycle of, 816
morphology of, 813, 816
taxonomy of, 811-813
transmission of, 816-817
- Giemsa stain, in pneumocystosis diagnosis, 966
- Gleason grading, for prostate cancer, 388
- Glucagonoma, cytology in, 350-351
- Glycerol, for worm clearing, 1048-1049
- Goiter, cytology in, 318
- Government, in laboratory regulation, 795-800
- Graft rejection, ABO antigen effects on, 537-550
accelerated, heart, atherosclerosis in, 589
kidney, 585
anti-idiotypic antibodies in. *See Anti-idiotypic antibodies.*
crossmatching in, 766-768
delayed hyperacute, kidney, 583, 585
donor-specific antibodies in. *See Antibody(ies), in transplantation, donor-specific.*
histocompatibility matching in, 763-766
HLA-Cw in, 581
HLA influence on, 537-550
clinical matching techniques and, 541-543
immune recognition in, 539-540
immunogenic determinants of, 540-541
presensitization and, 543-544
human monocyte antigen system in, 538
hyperacute, heart, 586-587, 589
kidney, 583
liver, 591, 593
pancreas, 595
immunosuppressive therapy monitoring in, 767-768
monitoring of, 653-670
exfoliative cytology in, 743-744
fine needle aspiration biopsy in, 743-744
heart, 663-664, 742-743
heart-lung, 664-665
kidney, 735-738, 744-749
urinary sediment cytology in, 744-749
liver. *See under Liver transplantation.*
lung, 664-665
lymphocyte surface markers in, 739-741
pancreas, 663
non-HLA antigens in. *See Antigen(s), non-HLA.*
OKT3 therapy in. *See OKT3 monoclonal antibodies.*
pathology in, heart, 586-587, 589
kidney, 583, 585
liver, 591, 593
pancreas, 595
therapy monitoring in, 693-714
urinary sediment cytology in, 744-749
vascular endothelial cell antigen system in, 538

- Graft rejection (*Continued*)
 with negative lymphocyte crossmatch, 622
- Granular cell tumor, of breast, cytology in, 360
- Granulocytic sarcoma, cytology in, 488-489
- Granuloma, liver, cytology in, 343
- Granulomatous amebic encephalitis, 866-869
- Granulomatous reactions, of lung, cytology in, 312
- Gynecologic cytology, 271-292
 Bethesda system for, 273-279
 combined cervicovaginal smear in, 272
 endocervical sampling in, 273, 283-284
 endometrial sampling in, 273
 in chlamydial infection, 282
 in endocervical adenocarcinoma, 282-286
 in endometrial lesions, 286-289
 in extrauterine adenocarcinoma, 289-290
 in human papillomavirus lesions, 281-282
 in inflammatory conditions, 280-282
 in squamous preneoplastic/early neoplastic lesions, 273-280
 sample adequacy for, 273
 techniques for, 272-273
 two-smear method for, 272
 V-C-E smears for, 272-273
- Gyneecomastia, cytology in, 362
- Hashimoto's thyroiditis, cytology in, 323-324
- Head and neck tumors, cytology in, 317-336
 cystic lesions, 334-335
 metastasis, 334
 paraganglioma, 333
 salivary glands, 325-332
 schwannoma, 332-333
 soft-tissue, 336
 thyroid, 317-324, 334
- Health Industry Business Communications Council, bar code standards of, 236-237
- Health Level 7 Standard, for information systems, 223, 240
- "Heart failure cells," in pulmonary cytology, 312
- Heart-lung transplantation, graft monitoring in, 664-665
- Heart transplantation, donor-specific antibodies in, 585-589
 graft monitoring in, 663-664, 742-743
- Heidenhain's iron alum-hematoxylin, in amebiasis diagnosis, 843
- HELP system, 140
- Hemagglutination test, indirect, in amebiasis, 851
 in American trypanosomiasis, 906
 in toxoplasmosis, 928
- Hemangioma, cavernous, of liver, cytology in, 340
- Hematology, expert systems for, 144-145
- Hematopoiesis, extramedullary, effusion cytology in, 462
- Hematoxylin stain, for worms, 1049-1050
- Hemosiderin, in pulmonary cytology, 312-313
- Hepatitis, in transplant patients, 657, 660, 718, 723, 727
- Hepatocellular adenoma, cytology in, 340
- Hepatocellular carcinoma, cytology in, 337-338
- Hepatocytes, cytology of, 337
- Herpes simplex virus infections, in transplant patients, 717, 721-722
- Herpes virus infections, cytology in, esophageal, 404-406
 pulmonary, 311
- Herpesvirus type 6 infection, in transplant patients, 717, 720
- High performance liquid chromatography, in cyclosporine A monitoring, 675-676
- Histiocytic infiltration, of stomach, cytology in, 420
- Histologic studies, in cryptosporidiosis, 883
- HIV infection. *See Human immunodeficiency virus infection.*
- HLA, 509-536
 alloimmunization to. *See under Alloimmunization.*
 antibodies to. *See also Antibody(ies), in transplantation, donor-specific.*
 posttransplant, 588-589
 class I, cellular subtypes of, 518
 crossreactivity of, 516-517
 functions of, 511
 in kidney graft rejection, 736
 in liver graft rejection, 660, 662
 polymorphisms of, definitions of, 515-522
 structural basis for, 519-522
 private antigen detection in, 517-518
 soluble, interference with anti-idiotypic antibody detection, 642
 structure of, 510
 typing of, 512-513
 class II, functions of, 511
 in liver graft rejection, 660
 polymorphisms of, definitions of, 522-531
 structural basis for, 529-531
 structure of, 510-511
 typing of, 513
 genetic basis of, 510-512
 genotyping of, 542
 haplotyping of, 542-543
 mismatching of. *See Mismatch, in transplantation.*
 polymorphisms of. *See also specific class.*

- definitions of, class I, 515-522
 - class II, 522-533
- determination of, 512-515
 - biochemical methods for, 514
 - cellular typing in, 513-514
 - class I typing in, 512-513
 - class II typing in, 513
 - molecular typing in, 515, 518-519
 - serology in, 512
- presensitization to, 543-544
- typing of, 512-513, 515, 518-519, 542-543, 734-735, 763-766
- HLA-Cw, in graft rejection, 581
- HLA-D alleles, molecular designation of, 528-529
- HLA-DQ, HLA-DRB associations of, 528
- HLA-DR, HLA-Dw associations of, 525
- HLA-DRB, HLA-DQ associations of, 528
- HLA-Dw, HLA-DR associations of, 525
- Hodgkin's disease, cytology in, 488-489
 - effusion, 460
- Home monitoring, data management in, 245
- Hospital laboratories, competitors of,
 - information system advantages over, 187-202
 - organizational changes as response to, 200-201
 - types of, 188-190
- quality of, 190-192
- services of, information systems in, 194-200
- users of, 192-194
- Human immunodeficiency virus infection,
 - cryptosporidiosis with, 881-883
 - in transplant patients, 718, 727-728
- Human lymphocyte/leukocyte antigen. *See* HLA.
- Human monocyte antigen system, 538, 624
- Human papillomavirus lesions, cervical,
 - cytology in, 281-282
- Hürthle cells, in thyroid nodules, 321, 323
- Hybrid laboratories, information systems
 - for, 45-46, 153-169
 - billing in, 161-166
 - client-specific requirements in, 167-168
 - in patient identification/tracking, 155-156
 - in specimen identification/tracking, 156-157
 - laboratory growth and, 154-155
 - operations in, 157-161
 - reporting considerations in, 158-161
- Idiotypes. *See also* *Anti-idiotypic antibodies*.
 - crossreactive, 636
 - networks of, 637-640
 - public, 636
 - regulatory, 636
- terminology of, 635-636
- Ileal conduit, urine specimen from, 375
- Immune complexes, circulating, in
 - amebiasis, 853
 - in transplantation, 579
- Immunoassay, in cyclosporine A monitoring,
 - affinity column-mediated, 678
 - chemiluminescence, 678
 - enzyme-multiplied, 678
 - fluorescence polarization, 677-678
- Immunoblastic lymphoma/sarcoma, cytology in, 483-484
- Immunodeficiency, cryptosporidiosis in, 881-883
 - toxoplasmosis in, 934-935
- Immunodiagnosis, of African
 - trypanosomiasis, 903
 - of amebiasis, 850-852
 - of American trypanosomiasis, 906
 - of cysticercosis, 1015-1018
 - of giardiasis, 821-823
 - of malaria, 948-949
 - of pneumocystosis, 970-971
- Immunoelectrophoresis, in American trypanosomiasis, 906-907
- Immunofluorescence assay, in endothelial crossmatch techniques, 624-625, 628-629
 - in giardiasis, 821-822
 - indirect, in amebiasis, 851
 - in free-living amebic infections, 865
- Immunofluorescent antibody test, in African trypanosomiasis, 903
 - in American trypanosomiasis, 906
- Immunofluorescent stain, in pneumocystosis diagnosis, 970
- Immunoglobulin A, detection of, in
 - toxoplasmosis, 935
- Immunoglobulin M, antiepitheial, 578
 - detection of, in African trypanosomiasis, 905
 - in amebiasis, 853
 - in giardiasis, 821
 - in toxoplasmosis, 929-931
- reactivity of, elimination of, in recipient serum preparation, 608
- removal of, before transplantation, 573
- Immunohistochemistry, in liver graft monitoring, 659-661
- Immunologic interventions, in
 - cryptosporidiosis, 888-889
- Immunoperoxidase stain, in pneumocystosis diagnosis, 970
- Immunophenotyping, in leukemia/lymphoma cytology, 474-475. *See also* specific type under *Lymphoma* and *Leukemia*.
- Immunosorbent agglutination test, in toxoplasmosis, 930

- Immunosuppressive drugs. See also
Cyclosporine A; *OKT3 monoclonal antibodies*.
in transplantation, 735
infections and, 716-717
monitoring of, 767-768
- Imprint sampling, from leishmaniasis lesion, 914
- Indirect fluorescent antibody test, in
filariasis, 995
in leishmaniasis, 920
in toxoplasmosis, 929-930
- Indirect hemagglutination test, in amebiasis, 851
in American trypanosomiasis, 906
in toxoplasmosis, 928
- Indirect immunofluorescence test, in amebiasis, 851
- Infant, toxoplasmosis diagnosis in, 933-934
- Infection, cytology in, bladder, 380
effusion, 462-463
lung, 295-296, 310-313
in transplant patients, 715-731
graft-versus-host reactions in, 717
immunosuppressive drugs and, 716-717
laboratory evaluation of, approach to, 723-725
types of, 722-723
viruses, 725-729
organ type and, 716
pathogen sources in, 717-719
pathogen types in, 719-721
pretransplant samples in, 722
risk factors in, 715-717
vs. rejection, 656-657
- Infertility, male, testicular biopsy in, 394
- Inflammation, cytology in, bladder, 380
esophageal, 406-407
gastric, 415-417
- Information systems, accessioning in, 98
accounting functions in, 87-88, 166
acquisition of, background information for, 9-11
issues in, 1-20
vendor selection for, 21-39
bar codes in, 227-238
billing functions of, 161-166
caveats in, 118, 120
check digit in, 87-88
communication in, 5-6, 46, 49-50
of test results, 184
peer-to-peer, 244
standards for, 222-223
to physician, 243-244
competitive advantages of, 187-202
computers in. See *Computers*.
consultation in, 8-9
contract for, 34-39
cost-benefits model for, 118
costs of, 105-106
external, 112
internal, 112-114
savings in, 114-117
data base access with, 129-130
data base centralization in, 223-224
data retrieval from, 217
data verification in, 99-100, 143-144
delta checking in, 100-101
design of, 83-104
patient-centered, 214-218
efficiency of, 108
errors in, 66-70
evolution of, 73-81
expert systems in, 135-150
fault tolerance in, 217
for first-time buyer, 107
for hybrid laboratories. See under *Hybrid laboratories*.
for nursing records, 206-208
for reference laboratory, 101-102
combined with hospital laboratory. See *Hybrid laboratories*.
history of, 73-81
image reports in, 242-243
implementation of, 41-51
in-house development of, 32-33
in scheduling, 215-216
test results, 179
information flow in, 12-13
instrument interface in, 99-100
invoice generation by, 165
justification of, 105-121
knowledge base in, 137-138, 146
laboratory needs analysis for, 11-13
leadership for, 8
literature search on, 110
medical record in, 209-211
Medicare system impact on, 208-209
multivendor type, 221-225
networks in, connection of, 221-225
disadvantages of, 211-214
expert systems in, 140
programming languages for, 60-61
software for, 48-49
workstation and, 125
open architecture of, 221-225
optimization of, 205-208
order entry in, 96-97, 141-142
order forms for, 255-265
paperless, 217
patient-centered, 203-220
personnel selection for, 7-8
physicians' offices interfaces in, 239-249
printers for, 177-178, 229
programming languages for. See *Languages, programming*.
project management in, 102
prospective analysis of, 110-118
replacement of, 107-108
reports in. See *Reports, of test results*.

- request for proposal for, 21-26
- result entry into, 98-99
- retrospective analysis of, 111-112
- scope of, 11-12
- security systems in, 159, 242
- selection of, 27-34
- specimen handling in, 142-143
- spreadsheets in, 60
- telecommunications in, 49-50
- training for, 49
- underconfiguration of, 47
- upgrading of, 38
- word processing in, 59-60
- workstations for, 70, 123-134, 183-184
 - applications of, 128-131
 - data display, 131-132
 - hardware perspective in, 123-124
 - productivity of, 129-130
 - software for, 124-125
 - user interface in, 126-128
- Inspection authorities, in Australia, 786-788
- Insulinoma, cytology in, 350-351
- Interleukin(s), in transplant recipient monitoring, 750-757
- Interleukin-2 receptors, in liver graft rejection, 662
- Intestinal metaplasia, in stomach, cytology in, 417-418
- Intestine, large. See *Colon*.
- Iodamoeba bütschlii*, 829, 845-847
- Iron hematoxylin, in amebiasis diagnosis, 843-844
- Islet cell tumors, cytology in, 350-351
- Isoenzyme analysis, in free-living amebic infections, 865

- Kaposi's sarcoma, of colon, cytology in, 436
- Keratinization, in cervical lesions, 279
- Keratinocytes, alloantigens in, 626-627
- Keratitis, *Acanthamoeba* in, 869-870
- Kidney transplantation, cytology in, 385-386
 - donor-specific antibodies in, 573-585
 - monitoring in, 735-738, 744-749
 - non-HLA antigens in. See *Antigen(s)*, non-HLA.
- Kidney tumors, cytology in, 381-387
 - angiomyolipoma, 384
 - cysts, 384-385
 - diagnostic value of, 385-386
 - limitations of, 386
 - oncocyoma, 384
 - pathology in, 382-385
 - renal cell carcinoma, 382, 384
 - safety of, 386-387
 - Wilm's, 384
- Knott procedure, for filariae concentration, 981

- Knowledge base, in laboratory information system, 137-138, 146
- Koilocytes, in cervical lesions, 281

- Laboratory information systems. See *Information systems*.
- Laboratory management, test requests in, decision-oriented, 255-265
- Laboratory regulation, historical aspects of,
 - commercialism in, 800-801
 - governmental role in, 795-800
 - origins of, 793-795
 - in Australia, 777-791
 - pathology of, 793-802
- Lactophenol, for worm clearing, 1048-1049
- Languages, programming, 6-7, 30-31, 53-72
 - combinatorial number problems in, 67-68
 - effectiveness and, 64-66
 - for networks, 60-61
 - for personal computers, 59-60
 - in top-down programming, 59, 66
 - object-oriented, 61-62
 - productivity and, 63-64
 - prototype, 65-66
 - simplicity in, 62-63
 - structure of, 55-57, 62-64
 - system robustness and, 66-70
 - transparency in, 58
 - variety of, 57-62
 - vs. applications, 58-59
- Large-cell carcinoma, cytology in, effusion, 454
 - lung, 309-310
- Large-cell lymphoma, cytology in, 484-485
- Large intestine. See *Colon*.
- Latex agglutination test, in toxoplasmosis, 929
- Lavage, for cytology, bronchoalveolar. See *Bronchoalveolar lavage*.
- colonic, 425-427, 431-433
- Leiomyoblastoma, of stomach, cytology in, 424
- Leiomyosarcoma, metastatic to liver, cytology in, 342
- Leishmaniasis, diagnosis of, 909-922
 - direct agglutination test in, 920
 - enzyme-linked immunosorbent assay in, 919-920
 - indirect fluorescent antibody test in, 920
- Montenegro skin test in, 919
- mucocutaneous, 911-919
 - amastigote visualization in, 912-917
 - lesion sampling in, 912-917
 - organism isolation in, 917-919
- serologic, 919-920

- Leishmaniasis (*Continued*)
 visceral, 911
- Lennert's lymphoma, cytology in, 495
- Leptomyxid amebae, in granulomatous encephalitis, 866-870
- Leu monoclonal antibodies, in CD3 cell detection, 705-706
 in graft monitoring, 739-740
- Leukemia, cytology in, 469-499
 acute lymphoblastic, 487-488
 chronic lymphocytic, 490-491
 classification of, 473-475
 effusion, 454-456, 460
 granulocytic sarcoma and, 486-487
 indications for, 471
 monomorphous processes in, 477-478
 multiparameter approach to, 471-472
 nucleic acid flow cytometry in, 475
 expert systems for, 145
- Lewis antigens, in bladder cancer, 381
- Lipid pneumonia, cytology in, 312
- Lipoma, cytology in, breast, 359-360
 head and neck, 336
- LIS. See *Information systems*.
- Lithiasis, urinary, cytology and, 380
- Liver, amebic abscess of, 849-850
- Liver transplantation, donor-specific antibodies in, 590-593
 monitoring in, 654-662
 bile cytology in, 661
 biochemical markers in, 658-659
 cellular methods in, 662
 cholestasis in, 658
 fine needle aspiration biopsy in, 655-659
 immunohistochemistry in, 659-661
 in acute rejection, 654-655
 inflammation in, 655-657
 liver enzyme levels in, 658-659
 lymphocyte growth studies in, 661
 needle biopsy in, 659
 noninvasive, 661-662
 parenchymal morphologic changes in, 658
 soluble marker detection in, 662
- Liver tumors, cytology in, 336-344
 benign, 343
 cavernous hemangioma, 340
 cholangiocarcinoma, 338, 340
 focal nodular hyperplasia, 340
 hepatocellular adenoma, 340
 hepatocellular carcinoma, 337-338
 mesenchymal, 340
 metastatic, 340-342
 sarcoma, 340
 vs. normal tissue, 337
 vs. parenchymal disease, 343
- Loa loa* infection. See *Filariasis*.
- Lobular carcinoma, breast, cytology in, 365
- Locke-egg media, for amebae cultivation, 847-848
- Lugol's stain, in amebiasis diagnosis, 838-839
- Lumbar puncture, in cysticercosis, 1018
- Lung disorders, *Acanthamoeba* infection, 871
 cytology in. See also *Pulmonary cytology*.
 abscess, 311
 adenocarcinoma, 301-306
 carcinoma, 294-295, 454
 needle aspiration in, 297-298
 infections, 295-296, 310-313
 large-cell carcinoma, 309-310
 small-cell carcinoma, 306-309
 squamous cell carcinoma, 298-300
 vs. adenocarcinoma, 303
- Lung transplantation, monitoring in, 664-665
- Lymph nodes, filariasis of, diagnosis of, 994-995, 998-1000
 lymphocyte isolation from, for transplantation crossmatching, 604
 needle aspiration of. See *Lymphoma, cytology in*.
 of neck, metastasis to, cytology in, 334
- Lympho-Kwik reagent, in lymphocyte isolation, for crossmatch procedures, 605
- Lymphoblastic leukemia, acute, cytology in, 487-488
- Lymphoblastic lymphoma, malignant, cytology in, 482-483
- Lymphocyte(s). See also *B cell(s)*; *T cell(s)*.
 blastogenesis of, in kidney graft monitoring, 738
 CD2, in CD3 cell detection, 705
 CD3, OKT3 monoclonal antibody reaction with, 693-695
 CD4, in graft monitoring, 739-740
 in heart graft monitoring, 742-743
 CD5, in CD3 cell detection, 705
 CD8, in graft monitoring, 739-740
 in heart graft monitoring, 742-743
 isolation of, for transplantation cross-matching, 604-606
- Lymphocyte-mediated cytotoxicity assay, in kidney graft monitoring, 737
- Lymphocyte surface markers, in transplant recipient monitoring, 739-741
- Lymphocyte tests, in transplantation, 531-532, 661
 antibodies missed by, 622
 chromium-release assays in, 615
 clinical relevance of, 615-617
 complement-dependent cytotoxicity assays in, 609-610, 641-642, 737
 flow cytometry in, 610-615
 historical aspects of, 604
 in heart graft monitoring, 742-743

- in HLA typing, 513-514
- in kidney graft monitoring, 737-738
- in liver graft monitoring, 662
- recipient sera for, 607-608
- target cell isolation in, 604-606
- Lymphocytic leukemia, chronic, cytology in, 490-491
- Lymphocytic lymphoma, cytology in, 490-491
- Lymphocytic thyroiditis, cytology in, 323-324
- Lymphoid infiltrates, of salivary glands, cytology in, 331
- Lymphokines, in transplant recipient monitoring, 750-757
- Lympholysis, cell-mediated, in HLA typing, 514, 544
- Lymphoma, cytology in, 469-499
 - classification of, 472-473
 - effusion, 454-456, 460
 - Hodgkin's disease, 460, 488-489
 - immunoblastic, 483-484
 - in partial node involvement, 496
 - indications for, 471
 - large-cell, 484-485
 - Lennert's, 495
 - malignant, 490-493
 - malignant lymphoblastic, 482-483
 - mixed-cell, 493-495
 - monomorphous processes in, 477-478
 - multiparameter approach in, 471-472
 - nucleic acid flow cytometry in, 475
 - salivary glands, 331
 - small cleaved-cell, 492-493
 - small lymphocytic plasmacytoid, 491-492
 - small noncleaved cell, 481-482
 - stomach, 419, 422
 - T-zone, 495
 - thyroid, 322-323
 - well-differentiated lymphocytic, 490-491
- Lymphoproliferative disorders, after transplantation, 721
- Magnetic immunobeads, in lymphocyte isolation for crossmatching, 605-606
- Magnetic resonance imaging, in cysticercosis, 1015
- Major histocompatibility complex. *See HLA.*
- Malaria, 941-956
 - clinical assessment of, 943
 - clinical symptoms of, 942-943
 - diagnosis of, biochemical, 951
 - centrifugal, 950-951
 - flow cytometry in, 949-950
 - fluorescent microscopy in, 947-948
 - immunologic methods in, 948-949
 - laboratory procedures for, 951
 - microscopic, 943, 945-948
 - nucleic acid, 951-953
 - polarized light microscopy in, 947
 - specimen collection/preparation for, 945-947
 - parasite of, 941
 - life cycle of, 942
 - risk factors for, 941
- Mancini method, in African trypanosomiasis diagnosis, 905
- Mansonella* infections. *See Filariasis.*
- Markers, for graft rejection, liver, 662
- pancreas, 663
- Massachusetts General Hospital Utility Multi-Programming System (MUMPS), 7, 30-31, 57, 76, 86
- Mastitis, cytology in, 359
- Medical Electrophoresis Analysis Interactive Expert system, 144
- Medical record, problems with, 209-211
- Medicare, cost reimbursement system of, 208-209
- MEDLINE, access to, 129
- Medullary carcinoma, cytology in, breast, 365
- thyroid, 321
- MEDX Standard, for information systems, 223, 240
- MELANIE expert system, 144
- Melanoma, cytology in, effusion, 457
- metastatic to liver, 341-342
- Membrane filtration, as concentration method, in filariasis diagnosis, 981-984
- Meningoencephalitis, amebic, 861-866
- Merthiolate iodine formalin, for stool specimens, 835
- Mesothelial repair, cytology in, 446-448
- Mesothelioma, malignant, effusion cytology in, 448, 457-460
- Metastasis, cytology in, to liver, 340-342
- to lung, 301-303
- to neck lymph nodes, 334
- Methenamine silver nitrate stain, in pneumocystosis diagnosis, 965
- Methylene blue dye test, in toxoplasmosis, 928
- Microfilariae. *See Filariasis.*
- Microlymphocytotoxicity assay, in transplantation testing, 609-610
- Microscopy, in free-living amebic infections, 863-864, 868-869
- in malaria diagnosis, 943, 945-948
- Millipore membranes, as concentration method, in filariasis diagnosis, 981-984
- Mini-anion exchange centrifugation test, in African trypanosomiasis, 904
- Minor histocompatibility antigens, in graft rejection, 622-624

- Mismatch, in transplantation, donor-specific antibodies and, 580
 poor, results of, 580-581, 735
 repeat antigen mismatch in, 580
 selective, results of, 565
 significance of, 542
 zero, 532-533
- Mixed lymphocyte culture, in HLA typing, 513
 in transplantation testing, 531-532
- Mixed lymphocyte reaction, sensitization detection by, 544
- Molecular technology, in amebiasis diagnosis, 854
 in filariasis diagnosis, 1000
- Molecular typing, in HLA analysis, 515, 518-519
- Monoclonal antibodies, in American trypanosomiasis diagnosis, 907
 in lymphocyte isolation, for crossmatch procedures, 606
 in pneumocystosis diagnosis, 971
 in transplant rejection. See under *OKT3 monoclonal antibodies*.
- Monocytes, endothelial antigens expressed on, 576-578, 624, 627-628
- Montenegro skin test, for leishmaniasis, 919
- Mott cells, in African trypanosomiasis, 904
- Mucinous carcinoma, breast, cytology in, 367
- Mucinous cystic neoplasm, of pancreas, cytology in, 351
- Mucocutaneous leishmaniasis. See under *Leishmaniasis*.
- Mucoepidermoid carcinoma, of salivary glands, cytology in, 327, 329
- Mucormycosis, pulmonary cytology in, 312
- MUMPS language, 7, 30-31, 57, 76, 86
- Mycoplasma infections, in transplant patients, 721
- Myocardium, biopsy of, in heart graft monitoring, 663-664, 742
- Naegleria fowleri*, in meningoencephalitis, 861-866
- National Association of Testing Authorities (Australia), 786-787
- National Pathology Accreditation Advisory alia)
 Council (Australia), 779-780
- Neck tumors. See *Head and neck tumors*.
- Needle aspiration, in graft monitoring, 743-744
 liver, 655-659
 pancreas, 663
 in leukemia. See *Leukemia, cytology in*.
 in lymphoma. See *Lymphoma, cytology in*.
- in pulmonary cytology, 297-298
 of breast lesions, 357-368
 of carotid body paraganglioma, 333
 of cystic neck lesions, 334
 of effusions. See *Effusion cytology*.
 of kidney, 382-387
 of leishmaniasis lesion, 914
 of liver tumors, 336-344
 of pancreatic tumors, 344-352
 of prostate, 387-393
 of salivary glands, 325-332
 of schwannoma, 332-333
 of thyroid, 317-324
- Needle biopsy, in liver graft monitoring, 659
- Neuroendocrine tumors, of stomach, cytology in, 422-423
- Nodular goiter, cytology in, 318
- Nucleic acid flow cytometry, in leukemia/lymphoma cytology, 475. See also specific type under *Lymphoma* and *Leukemia*.
- Nucleic acid hybridization methods, in cytomegalovirus detection, 728
 in filariasis diagnosis, 1000
 in malaria diagnosis, 951-953
- Nursing, clerical work in, 206-208
- Nylon wool columns, in lymphocyte isolation, for crossmatch procedures, 606
- Oat-cell carcinoma. See *Small-cell carcinoma*.
- OKT3 monoclonal antibodies, in transplantation, 693-714
 biopsy in, 707
 dosage of, 695
 first-dose reaction to, 696
 free antibody measurement in, 706
 immune response to, 700-703
 control of, 709-710
 in monitoring, 707-708
 in acute rejection, 695
 lymphokine assay in, 755-756
 monitoring of, 704-709, 740-741
 prophylactic, 695
 T-cell response to, 696-700, 704-706
 target antigen on T cells, 693-695
- OKT8 monoclonal antibodies, in transplantation, monitoring of, 739-740
- Oligonucleotide probes, sequence-specific, in HLA analysis, 515
- Onchocerciasis, 1001-1002, 1005
- Oncocytoma, renal, cytology in, 384
- Oocysts, of *Cryptosporidium*, 876-878
 atypical, 886-887
 environmentally resistant, 878-880
 laboratory examination of, 880-887
 low numbers of, 886

- reservoirs for, 880
- Open systems architecture, for information handling, 221-225
- Opportunistic infections, pulmonary cytology in, 310-313
- Ovarian cancer, cytology in, 289-290
- OVERSEER expert system, 146

- Pancreas transplantation, donor-specific antibodies in, 593-595
- monitoring in, 663
- Pancreatic juice cytology, in graft monitoring, 663
- Pancreatic tumors, cytology in, 344-352
 - acinar cell carcinoma, 349
 - cystic, 351
 - ductal adenocarcinoma, 345, 347
 - islet cell, 350-351
 - papillary-cystic, 349-350
 - vs. normal tissue, 345
 - vs. pancreatitis, 351
 - vs. pseudocyst, 351-352
- Pancreatitis, cytology in, 351
- Papillary carcinoma, cytology in, bladder, 370-372, 376-377, 380
- thyroid, 319-321
- Papillary cystadenoma lymphomatosum, of parotid, cytology in, 327
- Papillary-cystic neoplasm, of pancreas, cytology in, 349-350
- Papilloma, of breast ducts, cytology in, 362
- Papillomavirus infection, in transplant patients, 728
- Parabasal cells, atypical, in cervical lesions, 281-282
- Paraganglioma, carotid body, cytology in, 333
- Parasitic infections, acanthamoebic, 869-870
 - African trypanosomiasis, 899-905
 - amebiasis, 829-859
 - from free-living organisms, 861-872
 - amebic meningoencephalitis, 861-866
 - American trypanosomiasis, 905-908
 - Chagas disease, 905-908
 - cryptococcosis, in transplant patients, 725
 - cryptosporidiosis, 873-897
 - cysticercosis, 1011-1028
 - dermatitis, 870
 - effusion cytology in, 462
 - filariasis, 977-1010
 - giardiasis, 811-827
 - granulomatous amebic encephalitis, 866-870
 - keratitis, 870-871
 - leishmaniasis, 909-922
 - malaria, 941-956
 - onchocerciasis, 1001-1002, 1005
 - pneumocystosis, 312, 957-975
 - pneumonitis, 871
 - schistosomiasis, 1029-1039
 - sleeping sickness, 899-905
 - toxoplasmosis, 923-939
 - trypanosomiasis, 899-908
 - worms, 1041-1050
- Parasitologic diagnosis, of African trypanosomiasis, 903-904
 - of American trypanosomiasis, 907-908
 - of filariasis. See under *Filariasis*.
 - of toxoplasmosis, 926-927
- Paratope, definition of, 635-636
- Parotid gland tumors, cytology in, 325-332
- PASCAL, 59
- Pathology services, payment for. See under *Payment*.
- Patient identification/tracking, information systems for, 155-156
 - bar codes in, 234-235
- Patient proximity testing systems, vs. hospital laboratories, 190-195
- Payment, for pathology services, hospital-based, 1051-1063
 - billable services, 1052-1054
 - billing agent for, 1060-1061
 - coding for, 1057-1060
 - combination arrangements, 1055
 - contracting principles in, 1052
 - direct professional component billing, 1054
 - fee schedule for, 1056-1057
 - historical aspects of, 1051-1052
 - percentage arrangements, 1054-1055
 - salary arrangements, 1055
 - stipend arrangements, 1055
 - in Australia, 784-786
- Pemphigus vulgaris, esophageal, cytology in, 414
- Peptides, synthetic, in malaria immunodiagnosis, 949
- Pericardial fluid cytology. See *Effusion cytology*.
- Peritoneal fluid cytology. See *Effusion cytology*.
- Personnel, for information system acquisition, 7-9
- Phosphorylcholine assay, in filariasis diagnosis, 999-1000
- Physician's office, information systems for, 239-249
 - communication in, 243-244
 - home monitoring and, 245
 - image reports in, 242-243
 - interfaces for, 239-240
 - problems in, 247-248
 - services provided by, 245, 247
 - test performance in, 242
- Phytohemagglutinin test, in kidney graft monitoring, 738
- Pick programming language, 65

- Plasmacytoid lymphoma, cytology in, 491-492
- Plasmapheresis, in donor-specific antibody removal, 582
- Plasmodium*. See *Malaria, parasite of*.
- Pleomorphic adenoma, of salivary glands, cytology in, 326-327
- Pleural fluid cytology. See *Effusion cytology*.
- Pneumocystis carinii* infection. See *Pneumocystosis*.
- Pneumocystosis, clinical manifestations of, 959
- cytology in, 312
- diagnosis of, 957-975
- nonmorphologic, 970-971
- specimen collection for, 961
- specimen handling for, 961, 963
- stains for, 963, 965-966, 970
- epidemiology of, 958-959
- in AIDS, 958-959
- in transplant patients, 724
- parasite of, 957-958
- pathophysiology of, 959
- treatment of, 959-960
- Pneumonia, cytology in, infectious, 311-312
- lipid, 312
- pneumocystic. See *Pneumocystosis*.
- Pneumonitis, *Acanthamoeba* in, 871
- Polycarbonate membrane, as concentration method, in filariasis diagnosis, 981-984
- Polymerase chain reaction, in
- pneumocystosis diagnosis, 971
- in toxoplasmosis diagnosis, 935
- Polyvinyl alcohol fixative, for stool specimens, 833-834
- Practice guidelines, test request forms, 255-265
- Precipitins, gel-diffusion, in amebiasis, 851-852
- Pregnancy, toxoplasmosis in, 932-933
- Preservation, of stool specimens, 832-836
- formalin solutions for, 835-836
- merthiolate iodine formalin for, 835
- polyvinyl alcohol fixative for, 833-834
- Schaudinn's fixative for, 834-835
- sodium acetate-acetic acid-formalin fixative for, 836
- Primed lymphocyte test, in HLA typing, 513-514
- Printers, for bar codes, 229
- for information systems, 177-178
- Private antigens, in HLA class I, 517-518
- Programming languages. See *Languages, programming*.
- Prostate cancer, cytology in, 387-393
- cells found in, 389
- complications of, 392-393
- diagnostic value of, 391
- errors in, 392
- indications for, 389, 391
- limitations of, 391-392
- pathology and, 388
- Prostate hyperplasia, cytology in, 389
- Prostatitis, cytology in, 392
- Protein(s), urinary, in kidney graft monitoring, 735-736
- Protein A, in donor-specific antibody removal, 582
- Pseudocyst, pancreatic, cytology in, 351-352
- Pulmonary cytology, 293-315
- bronchial brushing/washing in, 295
- bronchoalveolar lavage in, 295-296
- in adenocarcinoma, 301-306
- in carcinoma, 454
- in large-cell carcinoma, 309-310
- in nonneoplastic disease, 310-313
- in small-cell carcinoma, 306-309
- in squamous cell carcinoma, 298-300
- needle aspiration in, 297-298
- of sputum, 294-295
- Pus, amebae detection in, 849-850
- Quality assurance, in Australia, 788
- Quantitative Buffy Coat apparatus, in malaria diagnosis, 950-951
- Radioimmunoassay, in American trypanosomiasis, 907
- in cyclosporine A monitoring, 674-677
- Radiology, in cysticercosis, 1015
- Radiotherapy, cell changes in, bladder, 380
- esophageal, 411-412
- prostate, 392
- Recipient sera, for transplantation crossmatching, 607-608
- Red blood cell rosetting, in lymphocyte isolation, for crossmatch procedures, 606
- RED expert system, 143
- Reference laboratory, as hospital laboratory competitor, 190-192, 197
- combined with hospital laboratory. See *Hybrid laboratories*.
- information systems for, 101-102
- Reflux esophagitis, cytology in, 406-407, 414-415
- Regulation. See *Laboratory regulation*.
- Rejection, of grafts. See *Graft rejection*.
- Renal cell carcinoma, cytology in, 382, 384, 386
- Reports, of test results, 171-185
- chart management and, 179-180
- completed specimen, 174-175
- cumulative, 89-96, 173-174
- electronic inquiry of, 183-184

- examples of, 181-183
- expert systems in, 144-146
- for patient type, 180-181
- grouping in, 178-179
- in hybrid laboratories, 158-161
- interim, 173
- layout design for, 175-178
- manual system for, 172
- scheduling of, 179
- sequencing in, 178-179
- test-by-test, 174
- turnaround time and, 190-191
- voice, 184
- Request for proposal, for information systems, 21-26
- Respiratory distress syndrome, data in, expert systems for, 145
- Restriction fragment length polymorphism analysis, in HLA analysis, 515
- Rheumatoid disease, effusion cytology in, 462
- River blindness (onchocerciasis), 1001-1002, 1005
- Royal Australian College of General Practitioners, 789-790
- Royal College of Pathologists of Australasia, 788-789
- Salivary gland tumors, cytology in, 325-332, 334
 - carcinoma, 327, 329, 331
 - lymphoid infiltrates, 331
 - pleomorphic adenoma, 326-327
 - reliability of, 331-332
 - sialadenitis, 331
 - vs. normal tissue, 326
 - Warthin's tumor, 327
- Sarcoma, cytology in, effusion, 456-457, 460
 - granulocytic, 488-489
 - head and neck, 336
 - immunoblastic, 483-484
 - Kaposi's, 436
 - liver, 340, 342
- Schaudinn's fixative, for stool specimens, 834-835
- Schistosomiasis, immunodiagnosis of, 1029-1039
 - commercial supplies for, 1036
 - cost estimates for, 1035-1036
 - enzyme-linked immunoelectrotransfer blot test in, 1034-1035
 - FAST-ELISA test in, 1031-1034
- Schwannoma, cytology in, 332-333
- Sclerosing adenosis, of breast, cytology in, 362
- Scrapings, from leishmaniasis lesion, 913-914
- Security systems, in information systems, 159, 242
- Serous cystadenoma, of pancreas, cytology in, 351
- Sheather's sugar solution, for oocyst concentration, 884
- Shell vial method, in cytomegalovirus infection, 728
- Sialadenitis, cytology in, 331
- Signet-ring carcinoma, in effusions, cytology in, 451
- Skin, *Acanthamoeba* infection of, 871
- microfilariae detection in, 984-985
- Skin antibodies, crossmatch procedures with, 578, 625-629
- Skin autoantibodies, in crossmatch procedures, 629
- Skin test, for leishmaniasis, 919
- Small-cell carcinoma, cytology in, cervical, 279-280
 - effusion, 451, 454
 - lung, 306-309
 - metastatic to liver, 342
- Small intestine, specimen from, in giardiasis diagnosis, 819-820
- Smears, cervicovaginal. See *Gynecologic cytology*.
- SMR expert system, 146
- Sodium acetate-acetic acid-formalin fixative, for stool specimens, 836
- Sodium chloride solution, for oocyst concentration, 884
- Soft-tissue tumors, of head and neck, cytology in, 336
- Software. See also *Languages, programming*.
 - approval of, 36-37
 - bugs in, 15-16, 66-70
 - for bar codes, 236-237
 - for windowing, 127-128
 - inefficient, 47
 - licensing agreement for, 38
 - maintenance of, 37-38, 48
 - network-based, 48-49
 - operating system, 124-125
 - risks of, 30-31
- Specimen handling, expert system use in, 142-143
 - information systems for, 156-157
- Spleen, lymphocyte isolation from, for transplantation crossmatching, 605
- Sputum, cytology of, 294-295
 - examination of, in transplant patients, 724
 - induced, in pneumocystosis diagnosis, 961
- Squamous cell carcinoma, cytology in, bladder, 371-372
 - cervical, human papillomavirus and, 281-282
 - preneoplastic/early neoplastic lesions and, 273-280

- Squamous cell carcinoma (*Continued*)
cystic, 334
effusion, 451
esophageal, 409-410
lung, 298-300, 303
metastatic, 334, 341
vs. adenocarcinoma, 303
- Squamous cell dysplasia, of esophagus, cytology in, 413-414
- Squamous intraepithelial lesions, cervical, cytology in, 276-280
- Staining, in parasitic disease diagnosis, amebiasis, permanent, 843-845
temporary, 839-840
cryptosporidiosis, 884-886
filariasis, 979-981
pneumocystosis, 963, 965-966, 970
worms, 1049-1050
- Stomach disorders, cytology in, 415-424
adenocarcinoma, 418-419
adenoma, 421-422
dysplasia, 421-422
epithelial repair, 415-417
gastritis, 415-416, 420, 423-424
histiocytic infiltration, 420
intestinal metaplasia, 417-418
lymphoma, 419, 422
neuroendocrine tumors, 422-423
stromal tumors, 424
- Stones, urinary, cytology in, 380
- Stool examination, in amebiasis, 831-845
concentration procedures for, 840-842
specimen collection for, 831-832
specimen number for, 832
specimen preservation for, 832-836
staining in, 842-844
temporary stains in, 838-839
temporary wet mounts in, 837-838
in cryptosporidiosis, 883-887
in cysticercosis, 1018-1020
in giardiasis, 818-819
parasite concentration in, 819, 884
- String test, in giardiasis, 820
- Stromal tumors, of stomach, cytology in, 424
- T cell(s), cross reactive, in alloantigen response, 539
cytotoxic, in kidney graft rejection, 737
regulation of, anti-idiotypic-like antibodies and, 646-647
response of, to OKT3 therapy, 696-700, 704-706
- T-cell antigen receptor, OKT3 monoclonal antibody reaction with, 693-695
- T-cell receptors, in alloantigen recognition, 540-541
- Taenia solium* infection. See *Cysticercosis*.
- Tapeworm, pig. See *Cysticercosis*.
- Teepol procedure, in filariae concentration, 982-983
- Telecommunications, in information systems, 49-50
- Test order, entry of, in information systems, 96-97, 141-142
forms for, 255-265
- Testicular tumors, cytology in, 393-394
- Thyroglossal duct cyst, cytology in, 334
- Thyroid gland disorders, cytology in, 317-324
anaplastic carcinoma, 322
follicular adenoma, 318-319
follicular carcinoma, 319
Hashimoto's thyroiditis, 323-324
malignant lymphoma, 322-323
medullary carcinoma, 321
nodular goiter, 318
papillary carcinoma, 319-321
pitfalls in, 324
thyroiditis, 323-324
vs. normal tissue, 318
- Tissue diagnosis, of granulomatous amebic encephalitis, 867
- Toluidine blue O stain, in pneumocystosis diagnosis, 965
- Total testing process, expert systems in, 135-136, 141-146
- Toxoplasmosis, 923-939
acquired, 925, 931-932
clinical types of, 925
congenital, 925, 932-933
diagnosis of, acquired, 931-932
antibody detection tests in, 928-931
antigen detection methods in, 931
commercial kits for, 931
congenital, 932-933
future prospects for, 935
immune status determination in, 931
in immunocompromised host, 934-935
in newborn infant, 933-934
ocular, 934
parasite identification in, 926-927
serologic techniques in, 927-931
specimen requirements for, 927-928
encephalitis in, 934-935
epidemiology of, 925-926
ocular, 925, 934
parasite of, identification of, 926-927
life cycle of, 923-925
transmission of, 923, 925
- Transfusions, pretransplant, in donor-specific antibody suppression, 582, 633-634, 644-645
- Transitional cell carcinoma, urinary cytology in, 377, 381
- Transplantation. See also specific organ.
alloimmunization in, anti-idiotypic-like antibodies in, 633-652
monitoring of, 551-570

- aspiration cytology in, 743-744
- criteria for, 531
- crossmatch procedures in. See *Cross-match procedures*.
- cyclosporine A monitoring in, 671-691
- donor-specific antibodies in, 571-602
- exfoliative cytology in, 743-744
- graft rejection/survival and. See *Graft rejection*.
- histocompatibility testing, 734-735
- HLA immunogenetics in, 509-536
- immunologic heterogeneity and, 733-762
- in vitro testing in, 733-762
- incompatibility in, 533
- infection evaluation in, 715-731
- lymphocyte surface markers in, 739-741
- lymphokines in, 750-757
- non-HLA antigens in, 621-632
- renal, cytology in, 385-386
- selective mismatch results in, 565
- urinary sediment cytology in, 744-749
- zero mismatches in, 532-533
- TREACT expert system, 145
- Trichrome, in amebiasis diagnosis, 843-844
- Trophozoites, of *Entamoeba histolytica*, 829-830, 845-847
- of *Giardia*, 813, 816, 823
- Tsetse fly, in trypanosomiasis transmission, 901-902
- Tuberculosis, in transplant patients, 722
- Tubular cells, in urinary sediment, in transplant monitoring, 745-749
- Tumors, cytology of. See *Cytology*.
- Ulcerative colitis, cytology in, 431-434
- Ureter, cancer of, cytology in, 377
- Urinary cytology, 369-381
 - as screening procedure, 374
 - cells found in, 371-373
 - diagnostic value of, 376-377, 380
 - errors in, 380-381
 - flow cytometry in, 381
 - history of, 370
 - in transplant recipient monitoring, 744-749
 - indications for, 373-374
 - Lewis antigens in, 381
 - limitations of, 380
 - pathology in, 370-371
 - specimens for, 374-375
- Urine culture, in transplant patients, 723
- Urothelial cancer, cytology in. See *Urinary cytology*.
- Uterus, endometrial conditions of. See *Endometrium*.
- V-C-E smear, for gynecologic cytology, 272-273
- Vaginal smears. See *Gynecologic cytology*.
- Varicella-zoster virus infection, in transplant patients, 717, 721-722, 726
- Vascular endothelial cell antigen system, in graft rejection, 538, 577
- Victorian Pathology Services Accreditation Board (Australia), 782-783
- Viral capsid antigen test, 727
- Viral infections, cytology in, effusion, 462
 - lung, 311
 - laboratory diagnosis of, 725-729
 - of liver graft, vs. rejection, 657, 660-661
- Visceral leishmaniasis, diagnosis of, 911
- Voice mail, in result reporting, 243
- Warthin's tumor, cytology in, 327
- Water, contamination of, giardiasis transmission in, 817
- Western blot test (enzyme-linked immunoelectrotransfer blot test), in cysticercosis, 1016-1017
 - in schistosomiasis, 1034-1035
- Wet mount, temporary, in amebiasis diagnosis, 837-838
- Wilm's tumor, cytology in, 384
- Word processing, 59-60
- Working Formulation, for lymphoproliferative disease, 471-472
- Workstations, for information systems. See under *Information systems*.
- World Health Organization, HLA nomenclature of, 516
- Worms and worm-like objects, 1041-1050
 - clearing procedures for, 1048-1049
 - examination of, 1044-1048
 - fixation/handling of, 1043-1044
 - flat, unsegmented, 1046-1047
 - long, flat, unsegmented, 1047
 - long, round, segmented, 1047-1048
 - long, round, unsegmented, legless, 1045-1046
 - staining of, 1049-1050
 - types submitted, 1041-1043
 - with legs, 1048
- Wright's stain, in pneumocystosis diagnosis, 966
- Wuchereria bancrofti* infection. See *Filariasis*.
- Zinc sulfate, for fecal specimen concentration, 840-842
 - for oocyst concentration, 884